GLP-1 receptor agonist therapy

Preclinical

GLP-1 receptor agonist therapy is one of 11 therapeutic programs targeting Obesity & Overweight. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Obesity & OverweightRecruiting

Obesity & OverweightPreclinical

Recruiting

Competition

Competitive Landscape

13 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 3

Ozempic

Novo Nordisk

Phase 2

2 4

Crestor

AstraZeneca

Preclinical

1 5

Semagludtide

Novo Nordisk

Phase 2

1 6

LUM-201

LLumos Pharma

Phase 2

1 7

Enobosarm

VVeru Inc.

Phase 2

1 8

Incretin-Based Treatment

JJohns Hopkins University

Preclinical

1 9

Spermidine

MMedical University of Graz

Preclinical

1 10

GLP-1 receptor agonist therapy

GGazi University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Anterior Ischemic Optic Neuropathy

NCT07846956

PreclinicalRecruiting

Obesity & Overweight

NCT07740291

Q2 2027

Not yet recruiting

Morbid Obesity

NCT07668765

Q4 2028

Recruiting

Obesity & Overweight

NCT07901777

Clinical

Trials by Indication[1]

Obesity & Overweight2 trials

Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study

Recruiting·YYuzuncu Yil University··NCT07901777·200 enrolled

Tirzepatide Impact Assessment: Exploring Health and Wellness Outcomes

Recruiting·TTexas Tech University·Preclinical·NCT07740291·27 enrolled

Anterior Ischemic Optic Neuropathy1 trial

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in Non-Diabetic Obese Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A Retrospective Real-World Study

Not yet recruiting·IIstanbul Saglik Bilimleri University··NCT07846956·28 enrolled

Morbid Obesity1 trial

Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment

Not yet recruiting·GGazi University··NCT07668765·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GLP-1 receptor agonist therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for GLP-1 receptor agonist therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gazi University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GGazi University

GLP-1 receptor agonist therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Trials by Indication[1]

Obesity & Overweight2 trials

Anterior Ischemic Optic Neuropathy1 trial

Morbid Obesity1 trial

References

Drug Info

Quick Facts

Related News